Clinical Trials Browser

Lymphoma, Multiple Myeloma

Squamous Cell Cancers of the Head and Neck

Neoplasm Metastasis, Cholangiocarcinoma

Head and Neck Neoplasms

Head and Neck Neoplasms

Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung

Esophageal Neoplasms

Head and Neck Neoplasms

Lung Neoplasms, Melanoma, Mouth Neoplasms

Advanced Solid Tumors

Advanced Squamous Non Small Cell Lung Cancer

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NSCLC Harboring NRG1 Fusion

Head and Neck Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Squamous Cell Carcinoma of Head and Neck

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Glioblastoma, Recurrence

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

EDDIS-a1

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

neoCHANCE-1

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

neoCHANCE-2

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

Afatinib in Advanced Refractory Urothelial Cancer

Pilot Trial for Treatment of Recurrent Glioblastoma

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

DELINOR